Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Seattle Genetics, Inc.    SGEN

SEATTLE GENETICS, INC. (SGEN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Seattle Genetics, Inc. : Seattle Genetics to Present ADCETRIS® and ASG-5ME Data at ASCO Annual Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2012 | 12:10am CEST

Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that data from two of its antibody-drug conjugate (ADC) programs, ADCETRIS (brentuximab vedotin) and ASG-5ME, will be presented at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting being held June 1-5, 2012 in Chicago, IL. A summary of the company's poster presentations is below and full abstracts can be accessed on the ASCO website at www.abstract.asco.org.

ADCETRIS

Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: a phase II study

  • Saturday, June 2; 8:00 a.m. - 1:00 p.m. Central Time (CT), with discussion from 12:00 p.m. - 1:00 p.m. CT
  • Abstract # 8027
  • Poster display in room E450b and discussion in room E354a
  • First author: Dr. Nancy L. Bartlett, Washington University, Siteman Cancer Center, St. Louis, MO

CD30 expression in non-lymphomatous malignancies

  • Monday, June 4; 8:00 a.m. - 12:00 p.m. CT
  • Abstract #3069
  • Poster presentation in S Hall A2; poster board #16C
  • First author: Dr. Jeff P. Sharman, Willamette Valley Center Institute and Research Center, Eugene, OR

Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: preliminary results from a phase II study

  • Monday, June 4; 1:15 p.m. - 5:15 p.m. CT
  • Abstract #8070
  • Poster presentation in S Hall A2; poster board #35C
  • First author: Dr. Ranjana Advani, Stanford University Medical Center, Stanford, CA

ASG-5ME

Phase 1 trial of ASG-5ME in metastatic castration-resistant prostate cancer (CRPC)

  • Monday, June 4; 8:00 a.m. - 12:00 p.m. CT, with discussion from 11:30 a.m. - 12:30 p.m. CT
  • Abstract #4568
  • Poster display in room E450a and discussion in room E Arie Crown Theater
  • First author: Dr. Michael J. Morris, Memorial Sloan Kettering Cancer Center, New York, NY

About ADCETRIS

ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics' proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

Seattle Genetics and Millennium: The Takeda Oncology Company are jointly developing ADCETRIS.

Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and the Takeda Group has rights to commercialize ADCETRIS in the rest of the world. Seattle Genetics and the Takeda Group are funding joint development costs for ADCETRIS on a 50:50 basis, except in Japan where the Takeda Group is solely responsible for development costs.

About ASG-5ME

ASG-5ME is an ADC targeting the SLC44A4 antigen and is being co-developed by Seattle Genetics and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., for the treatment of solid tumors. ASG-5ME is an ADC composed of a fully human antibody directed to SLC44A4, a solute carrier antigen family member identified by Agensys to be overexpressed in epithelial cancers, including more than 80 percent of samples derived from patients with prostate, pancreatic and gastric cancers. The antibody is attached to MMAE via an enzyme-cleavable linker using Seattle Genetics' proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into SLC44A4-expressing tumor cells, resulting in targeted cell-killing.

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The U.S. Food and Drug Administration granted accelerated approval of ADCETRIS in August 2011 for two indications. ADCETRIS is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has three other clinical-stage ADC programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at www.seattlegenetics.com.

Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
[email protected]


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SEATTLE GENETICS, INC.
06/21SEATTLE GENETICS : Announces First Patient Dosed in Phase 2 Trial of Tisotumab V..
AQ
06/15SEATTLE GENETICS : Announces First Patient Dosed in Phase 2 Trial of Tisotumab V..
AQ
06/14SEATTLE GENETICS : and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Pa..
AQ
06/14ASTELLAS PHARMA : and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedoti..
AQ
06/14SEATTLE GENETICS : Announces First Patient Dosed in Phase 2 Trial of Tisotumab V..
AQ
06/13SEATTLE GENETICS : Announces First Patient Dosed in Phase 2 Trial of Tisotumab V..
BU
06/07SEATTLE GENETICS, INC. : Today's Free Research Reports Coverage on Seattle Genet..
AC
06/06SEATTLE GENETICS : to Present at the Goldman Sachs 39th Annual Global Healthcare..
BU
06/05ASTELLAS PHARMA : and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedoti..
AQ
06/04SEATTLE GENETICS : Highlights Additional Analyses from Phase 3 ECHELON-1 Clinica..
BU
More news
News from SeekingAlpha
06/15YOUR DAILY PHARMA SCOOP : Wright Receives PMA, Allergan And Corbus Report Positi.. 
06/14Autolus Therapeutics Readies $125 Million U.S. IPO 
06/13Seattle Genetics commences mid-stage study of tisotumab vedotin in cervical c.. 
06/11Premarket analyst action - healthcare 
06/07CORE BIOTECH BUYS #18 : Thoughts On ASCO And The End Of Core Biotech 
Financials ($)
Sales 2018 601 M
EBIT 2018 -261 M
Net income 2018 -276 M
Finance 2018 526 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 16,7x
EV / Sales 2019 12,8x
Capitalization 10 563 M
Chart SEATTLE GENETICS, INC.
Duration : Period :
Seattle Genetics, Inc. Technical Analysis Chart | SGEN | US8125781026 | 4-Traders
Technical analysis trends SEATTLE GENETICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 67,3 $
Spread / Average Target 1,1%
EPS Revisions
Managers
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson CFO & Principal Accounting Officer
Vaughn B. Himes Chief Technical Officer
Roger D. Dansey Chief Medical Officer
Srinivas Akkaraju Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SEATTLE GENETICS, INC.22.95%10 563
CELLTRION, INC.--.--%33 064
IQVIA HOLDINGS INC6.98%21 789
LONZA GROUP2.35%20 356
INCYTE CORPORATION-22.94%15 565
ALNYLAM PHARMACEUTICALS, INC.-17.65%10 581